Goldman Sachs Group Inc Immunity Bio, Inc. Transaction History

Goldman Sachs Group Inc

$780 Billion
Q3 2025

A detailed history of Goldman Sachs Group Inc transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,140,683 shares of IBRX stock, worth $2.37 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,140,683

Previous 831,206 37.23%

Holding current value

$2.37 Million

Previous $2.19 Million 27.89%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$2.24 - $3.01 $693,228 - $931,525	309,477 Added 37.23%	1,140,683 $2.81 Million
Q2 2025 Aug 14, 2025	SELL	$1.89 - $3.44 $426,559 - $776,383	-225,693 Reduced 21.35%	831,206 $2.19 Million
Q1 2025 May 09, 2025	SELL	$2.32 - $3.9 $196,357 - $330,084	-84,637 Reduced 7.41%	1,056,899 $3.18 Million
Q4 2024 Feb 11, 2025	SELL	$2.56 - $6.17 $377,269 - $909,279	-147,371 Reduced 11.43%	1,141,536 $2.92 Million
Q3 2024 Nov 14, 2024	BUY	$3.32 - $6.7 $876,254 - $1.77 Million	263,932 Added 25.75%	1,288,907 $4.78 Million

Q2 2024 Aug 13, 2024	SELL	$4.82 - $9.15 $917,756 - $1.74 Million	-190,406 Reduced 15.67%	1,024,975 $6.48 Million
Q1 2024 May 15, 2024	SELL	$3.23 - $6.17 $204,320 - $390,295	-63,257 Reduced 4.95%	1,215,381 $6.53 Million
Q4 2023 Feb 13, 2024	BUY	$1.25 - $5.21 $1.06 Million - $4.43 Million	850,874 Added 198.91%	1,278,638 $6.42 Million
Q3 2023 May 14, 2024	SELL	$1.29 - $3.1 $1.1 Million - $2.64 Million	-850,874 Reduced 66.55%	427,764 $722,000
Q3 2023 Nov 14, 2023	BUY	$1.29 - $3.1 $199,490 - $479,396	154,644 Added 56.62%	427,764 $722,000
Q2 2023 May 14, 2024	SELL	$1.53 - $6.41 $123,074 - $515,626	-80,441 Reduced 22.75%	273,120 $759,000
Q2 2023 Aug 14, 2023	SELL	$1.53 - $6.41 $123,074 - $515,626	-80,441 Reduced 22.75%	273,120 $759,000
Q1 2023 May 14, 2024	SELL	$1.35 - $4.78 $1.08 Million - $3.82 Million	-798,163 Reduced 69.3%	353,561 $643,000
Q1 2023 May 11, 2023	SELL	$1.35 - $4.78 $1.08 Million - $3.82 Million	-798,163 Reduced 69.3%	353,561 $643,000
Q4 2022 May 14, 2024	BUY	$4.35 - $6.77 $2.55 Million - $3.97 Million	585,881 Added 103.54%	1,151,724 $5.84 Million
Q4 2022 Feb 13, 2023	BUY	$4.35 - $6.77 $2.55 Million - $3.97 Million	585,881 Added 103.54%	1,151,724 $5.84 Million
Q3 2022 May 14, 2024	SELL	$3.65 - $6.43 $18,239 - $32,130	-4,997 Reduced 0.88%	565,843 $2.81 Million
Q3 2022 Nov 10, 2022	SELL	$3.65 - $6.43 $18,239 - $32,130	-4,997 Reduced 0.88%	565,843 $2.81 Million
Q2 2022 May 14, 2024	SELL	$2.68 - $6.14 $1.9 Million - $4.35 Million	-707,798 Reduced 55.36%	570,840 $2.12 Million
Q2 2022 Aug 15, 2022	BUY	$2.68 - $6.14 $435,942 - $998,763	162,665 Added 39.85%	570,840 $2.12 Million
Q1 2022 May 16, 2022	BUY	$5.05 - $7.53 $739,703 - $1.1 Million	146,476 Added 55.97%	408,175 $2.29 Million
Q4 2021 Feb 14, 2022	BUY	$5.67 - $10.18 $203,847 - $365,991	35,952 Added 15.93%	261,699 $1.59 Million
Q3 2021 Nov 10, 2021	BUY	$9.17 - $14.24 $2.07 Million - $3.21 Million	225,747 New	225,747 $2.2 Million

Others Institutions Holding IBRX

# of Institutions

297

Shares Held

137M

Call Options Held

2.59M

Put Options Held

3.35M

View Full List

About ImmunityBio, Inc.

Ticker IBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 400,304,000
Market Cap $833M
Description
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...

More about IBRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Immunity Bio, Inc. Transaction History